id	sid	eid	entity	type
dpc-3895	2	1	2024;14(2):e2024119 1	DATE
dpc-3895	2	2	208 week	DATE
dpc-3895	2	3	greek	NORP
dpc-3895	2	4	kyrmanidou1	PERSON
dpc-3895	2	5	christina kemanetzi1	PERSON
dpc-3895	2	6	stavros2	WORK_OF_ART
dpc-3895	2	7	myrto-georgia	GPE
dpc-3895	2	8	trakatelli1	GPE
dpc-3895	2	9	patsatsi1	GPE
dpc-3895	2	10	xenia madia3	GPE
dpc-3895	2	11	ignatiadi3	PERSON
dpc-3895	2	12	kalloniati1	GPE
dpc-3895	2	13	zoe apalla1	PERSON
dpc-3895	2	14	lazaridou1 1	LAW
dpc-3895	2	15	second	ORDINAL
dpc-3895	2	16	aristotle university	ORG
dpc-3895	2	17	thessaloniki	GPE
dpc-3895	2	18	thessaloniki	GPE
dpc-3895	2	19	greece 2 school of statistics	ORG
dpc-3895	2	20	university of western macedonia	ORG
dpc-3895	2	21	kozani	ORG
dpc-3895	2	22	greece 3	FAC
dpc-3895	2	23	athens	GPE
dpc-3895	2	24	greece	GPE
dpc-3895	2	25	secukinumab	GPE
dpc-3895	2	26	greece	GPE
dpc-3895	2	27	stavros c	GPE
dpc-3895	3	1	208 week	DATE
dpc-3895	3	2	greek	NORP
dpc-3895	5	1	2024;14(2):e2024119	CARDINAL
dpc-3895	5	2	december 14	DATE
dpc-3895	5	3	2023	CARDINAL
dpc-3895	6	1	april 2024	DATE
dpc-3895	6	2	2024 kyrmanidou	QUANTITY
dpc-3895	7	1	https://creativecommons.org/licenses/by-nc/4.0/	ORG
dpc-3895	8	1	novartis	GPE
dpc-3895	8	2	greece	GPE
dpc-3895	11	1	77	CARDINAL
dpc-3895	11	2	55132	CARDINAL
dpc-3895	11	3	thessaloniki	FAC
dpc-3895	13	1	ekyrmanidou@gmail.com	CARDINAL
dpc-3895	14	1	secukinumab	PERSON
dpc-3895	14	2	il-17a	PRODUCT
dpc-3895	15	1	greece	GPE
dpc-3895	16	1	2	CARDINAL
dpc-3895	17	1	2024;14(2):e2024119	CARDINAL
dpc-3895	17	2	the united states	GPE
dpc-3895	17	3	3%	PERCENT
dpc-3895	17	4	1	CARDINAL
dpc-3895	18	1	90%	PERCENT
dpc-3895	18	2	23%-27%	PERCENT
dpc-3895	18	3	49%	PERCENT
dpc-3895	18	4	12%-16%	PERCENT
dpc-3895	18	5	21%-30%	PERCENT
dpc-3895	19	1	2	CARDINAL
dpc-3895	20	1	≤ 1%	PERCENT
dpc-3895	20	2	bsa	ORG
dpc-3895	21	1	3	CARDINAL
dpc-3895	23	1	interleukin-23	LOC
dpc-3895	23	2	17a	CARDINAL
dpc-3895	23	3	il-17a	PRODUCT
dpc-3895	24	1	secukinumab	PERSON
dpc-3895	24	2	il-17a	PRODUCT
dpc-3895	24	3	1-9	CARDINAL
dpc-3895	25	1	secukinumab	PERSON
dpc-3895	25	2	first	ORDINAL
dpc-3895	26	1	secukinumab	PERSON
dpc-3895	26	2	4,5	CARDINAL
dpc-3895	27	1	second	ORDINAL
dpc-3895	27	2	the aristotle university of thessaloniki	ORG
dpc-3895	29	1	300 mg	QUANTITY
dpc-3895	30	1	2015 to 2020	DATE
dpc-3895	31	1	75	CARDINAL
dpc-3895	31	2	week 16 and week 52	DATE
dpc-3895	32	1	week 16	DATE
dpc-3895	32	2	±1	PERSON
dpc-3895	32	3	week 104	DATE
dpc-3895	32	4	week 156	DATE
dpc-3895	32	5	week 208	DATE
dpc-3895	33	1	ninety-nine	CARDINAL
dpc-3895	33	2	sixty six	CARDINAL
dpc-3895	33	3	66.67%	PERCENT
dpc-3895	33	4	33	CARDINAL
dpc-3895	34	1	74.74%	PERCENT
dpc-3895	34	2	74/99	CARDINAL
dpc-3895	34	3	27.27%	PERCENT
dpc-3895	34	4	27/99	CARDINAL
dpc-3895	34	5	17%	PERCENT
dpc-3895	34	6	17/99	CARDINAL
dpc-3895	35	1	week 16	DATE
dpc-3895	35	2	87.5%/69.8%/49%	PERCENT
dpc-3895	36	1	week 4	DATE
dpc-3895	36	2	fold	CARDINAL
dpc-3895	36	3	84.1%	PERCENT
dpc-3895	36	4	0/1	CARDINAL
dpc-3895	37	1	secukinumab	PERSON
dpc-3895	37	2	the 208 weeks	DATE
dpc-3895	38	1	5 weeks	DATE
dpc-3895	39	1	4-year	DATE
dpc-3895	39	2	greece	GPE
dpc-3895	41	1	2024;14(2):e2024119	CARDINAL
dpc-3895	41	2	3	CARDINAL
dpc-3895	42	1	4	CARDINAL
dpc-3895	42	2	16	DATE
dpc-3895	42	3	52	DATE
dpc-3895	42	4	104	ORG
dpc-3895	42	5	208 weeks	DATE
dpc-3895	42	6	± 1 week	DATE
dpc-3895	42	7	secukinumab	PERSON
dpc-3895	43	1	300 mg	QUANTITY
dpc-3895	44	1	2015 to 2020	DATE
dpc-3895	46	1	(≥6 months	DATE
dpc-3895	46	2	secukinumab	PERSON
dpc-3895	46	3	16 weeks	DATE
dpc-3895	47	1	10	CARDINAL
dpc-3895	47	2	at least 3	CARDINAL
dpc-3895	50	1	week 16 and week 52	DATE
dpc-3895	51	1	week 16	DATE
dpc-3895	51	2	±1	PERSON
dpc-3895	51	3	week 104	DATE
dpc-3895	51	4	week 156(±1	DATE
dpc-3895	51	5	week 208	DATE
dpc-3895	51	6	a. absolute pasi	PERSON
dpc-3895	51	7	pasi90	ORG
dpc-3895	51	8	0/1	CARDINAL
dpc-3895	51	9	spga	ORG
dpc-3895	51	10	ae	ORG
dpc-3895	51	11	saes	PERSON
dpc-3895	51	12	ae	ORG
dpc-3895	51	13	week 52	DATE
dpc-3895	51	14	104	CARDINAL
dpc-3895	54	1	5%	PERCENT
dpc-3895	56	1	fisher	ORG
dpc-3895	56	2	whitney u-test	PERSON
dpc-3895	60	1	ibm	ORG
dpc-3895	60	2	27.0	CARDINAL
dpc-3895	60	3	ibm	ORG
dpc-3895	61	1	0.05	CARDINAL
dpc-3895	62	1	ninety-nine	CARDINAL
dpc-3895	62	2	1	CARDINAL
dpc-3895	62	3	74	DATE
dpc-3895	62	4	74.75%	PERCENT
dpc-3895	62	5	27	CARDINAL
dpc-3895	62	6	27.27%	PERCENT
dpc-3895	62	7	17 (	PERCENT
dpc-3895	62	8	17.17%	PERCENT
dpc-3895	62	9	32	DATE
dpc-3895	62	10	32.32%	PERCENT
dpc-3895	63	1	sixty-six	CARDINAL
dpc-3895	63	2	66.67%	PERCENT
dpc-3895	63	3	33	CARDINAL
dpc-3895	64	1	12	CARDINAL
dpc-3895	64	2	one	CARDINAL
dpc-3895	64	3	12	CARDINAL
dpc-3895	64	4	two	CARDINAL
dpc-3895	64	5	5	CARDINAL
dpc-3895	64	6	3	CARDINAL
dpc-3895	65	1	17.17%	PERCENT
dpc-3895	65	2	17/99	CARDINAL
dpc-3895	65	3	11.11%	PERCENT
dpc-3895	65	4	11/99	CARDINAL
dpc-3895	65	5	12	CARDINAL
dpc-3895	65	6	12/99	CARDINAL
dpc-3895	65	7	10.10%	PERCENT
dpc-3895	65	8	10/99	CARDINAL
dpc-3895	65	9	2.02%	PERCENT
dpc-3895	65	10	2/99	CARDINAL
dpc-3895	65	11	adalimumab	PERSON
dpc-3895	66	1	pde4	ORG
dpc-3895	66	2	14.14%	PERCENT
dpc-3895	66	3	14/99	CARDINAL
dpc-3895	67	1	29.3	CARDINAL
dpc-3895	68	1	15	CARDINAL
dpc-3895	68	2	15.15%	PERCENT
dpc-3895	68	3	42	CARDINAL
dpc-3895	68	4	42.42%	PERCENT
dpc-3895	68	5	19	CARDINAL
dpc-3895	68	6	19.19%	PERCENT
dpc-3895	68	7	8	CARDINAL
dpc-3895	68	8	8.08%	PERCENT
dpc-3895	69	1	53	CARDINAL
dpc-3895	69	2	53.54%	PERCENT
dpc-3895	69	3	4	CARDINAL
dpc-3895	70	1	2024;14(2):e2024119	CARDINAL
dpc-3895	70	2	secukinumab	GPE
dpc-3895	70	3	week 16	DATE
dpc-3895	70	4	84/96	CARDINAL
dpc-3895	70	5	87.5%	PERCENT
dpc-3895	70	6	67/96	CARDINAL
dpc-3895	70	7	69.8%	PERCENT
dpc-3895	70	8	49%	PERCENT
dpc-3895	70	9	table2	GPE
dpc-3895	71	1	week 52	DATE
dpc-3895	71	2	pasi90	ORG
dpc-3895	71	3	86.4%/77.8%/43.2%	PERCENT
dpc-3895	71	4	week 104	DATE
dpc-3895	72	1	94.5%/78.2%/47.3%	PERCENT
dpc-3895	72	2	9	CARDINAL
dpc-3895	72	3	208 weeks	DATE
dpc-3895	72	4	88.9%/100%	PERCENT
dpc-3895	72	5	2	CARDINAL
dpc-3895	73	1	weeks 52	DATE
dpc-3895	73	2	104	ORG
dpc-3895	73	3	bsa	ORG
dpc-3895	73	4	5	CARDINAL
dpc-3895	73	5	5.05%	PERCENT
dpc-3895	73	6	one	CARDINAL
dpc-3895	73	7	30	CARDINAL
dpc-3895	73	8	30.30%	PERCENT
dpc-3895	73	9	two	CARDINAL
dpc-3895	73	10	11	DATE
dpc-3895	73	11	11.11%	PERCENT
dpc-3895	73	12	3	CARDINAL
dpc-3895	74	1	17.17%	PERCENT
dpc-3895	74	2	10	CARDINAL
dpc-3895	76	1	92/99	CARDINAL
dpc-3895	76	2	93%	PERCENT
dpc-3895	76	3	first	ORDINAL
dpc-3895	76	4	week 4	DATE
dpc-3895	77	1	two	CARDINAL
dpc-3895	77	2	12 weeks	DATE
dpc-3895	77	3	4-week 16	DATE
dpc-3895	77	4	24 weeks	DATE
dpc-3895	77	5	60-week	DATE
dpc-3895	78	1	four	CARDINAL
dpc-3895	78	2	two	CARDINAL
dpc-3895	78	3	week 8	DATE
dpc-3895	78	4	week 84	DATE
dpc-3895	79	1	bsa	ORG
dpc-3895	79	2	spga	ORG
dpc-3895	79	3	12.7	CARDINAL
dpc-3895	79	4	27.14	CARDINAL
dpc-3895	79	5	2.2	CARDINAL
dpc-3895	79	6	11.68	CARDINAL
dpc-3895	80	1	1	CARDINAL
dpc-3895	80	2	99	CARDINAL
dpc-3895	81	1	n n %	GPE
dpc-3895	81	2	99 50	CARDINAL
dpc-3895	81	3	23-76	CARDINAL
dpc-3895	81	4	99	CARDINAL
dpc-3895	81	5	53.5	CARDINAL
dpc-3895	82	1	99	CARDINAL
dpc-3895	83	1	17.98	CARDINAL
dpc-3895	84	1	99	CARDINAL
dpc-3895	85	1	4.88	CARDINAL
dpc-3895	85	2	bsa	ORG
dpc-3895	85	3	99 27.14	CARDINAL
dpc-3895	85	4	12.01	CARDINAL
dpc-3895	85	5	99 12.7	CARDINAL
dpc-3895	86	1	3.94	CARDINAL
dpc-3895	86	2	99 11.68	CARDINAL
dpc-3895	87	1	2.95	CARDINAL
dpc-3895	87	2	99 32 32.32	DATE
dpc-3895	87	3	99	CARDINAL
dpc-3895	87	4	66 66.67	CARDINAL
dpc-3895	87	5	61/99 61 61.61	CARDINAL
dpc-3895	87	6	33	CARDINAL
dpc-3895	87	7	99	CARDINAL
dpc-3895	87	8	66.67	CARDINAL
dpc-3895	87	9	99	CARDINAL
dpc-3895	87	10	27.27	CARDINAL
dpc-3895	87	11	99 74 74.74	CARDINAL
dpc-3895	87	12	99 17	CARDINAL
dpc-3895	87	13	17.17	CARDINAL
dpc-3895	87	14	99	CARDINAL
dpc-3895	87	15	49.49	CARDINAL
dpc-3895	87	16	99 42 42.42	CARDINAL
dpc-3895	87	17	99	CARDINAL
dpc-3895	87	18	99 12 12.12	DATE
dpc-3895	87	19	99 8 8.08	CARDINAL
dpc-3895	87	20	7.07	CARDINAL
dpc-3895	87	21	99	CARDINAL
dpc-3895	87	22	6.06	CARDINAL
dpc-3895	87	23	99 3 3.03	CARDINAL
dpc-3895	87	24	99 3 3.03	CARDINAL
dpc-3895	87	25	99 17 17.17	CARDINAL
dpc-3895	87	26	99	CARDINAL
dpc-3895	88	1	53.53	CARDINAL
dpc-3895	88	2	3 99	CARDINAL
dpc-3895	88	3	11.11	CARDINAL
dpc-3895	88	4	bsa	ORG
dpc-3895	90	1	2024;14(2):e2024119	CARDINAL
dpc-3895	90	2	16	CARDINAL
dpc-3895	91	1	one	CARDINAL
dpc-3895	91	2	week 108	DATE
dpc-3895	92	1	the 208 weeks	DATE
dpc-3895	93	1	week 16	DATE
dpc-3895	93	2	week 208	DATE
dpc-3895	93	3	11	CARDINAL
dpc-3895	93	4	104 weeks	DATE
dpc-3895	93	5	3	CARDINAL
dpc-3895	94	1	three	CARDINAL
dpc-3895	96	1	secukinumab	PERSON
dpc-3895	96	2	greece	GPE
dpc-3895	98	1	bio-naïve	PERSON
dpc-3895	99	1	almost half	CARDINAL
dpc-3895	99	2	at least one	CARDINAL
dpc-3895	100	1	secukinumab	PERSON
dpc-3895	100	2	over half	CARDINAL
dpc-3895	100	3	55.6%	PERCENT
dpc-3895	100	4	one	CARDINAL
dpc-3895	100	5	four	CARDINAL
dpc-3895	100	6	25.3%	PERCENT
dpc-3895	100	7	pasi90	ORG
dpc-3895	100	8	week 4	DATE
dpc-3895	101	1	week 16	DATE
dpc-3895	101	2	87.5%/69.8%/49%	PERCENT
dpc-3895	102	1	secukinumab	PERSON
dpc-3895	103	1	week 16	DATE
dpc-3895	103	2	86.1%/69.8%/41.6%	PERCENT
dpc-3895	103	3	5	CARDINAL
dpc-3895	104	1	rompoti et al	PERSON
dpc-3895	104	2	greece	GPE
dpc-3895	104	3	week 16	DATE
dpc-3895	104	4	83.3%/70%/46.3%	PERCENT
dpc-3895	104	5	6	CARDINAL
dpc-3895	105	1	greece	GPE
dpc-3895	106	1	29.3	CARDINAL
dpc-3895	106	2	18.4	CARDINAL
dpc-3895	106	3	29.1	CARDINAL
dpc-3895	106	4	17.3-50.2	CARDINAL
dpc-3895	106	5	almost half	CARDINAL
dpc-3895	106	6	at least one	CARDINAL
dpc-3895	106	7	46%	PERCENT
dpc-3895	106	8	49.4%	PERCENT
dpc-3895	107	1	32.3%	PERCENT
dpc-3895	107	2	43.2%	PERCENT
dpc-3895	107	3	20%	PERCENT
dpc-3895	108	1	bai et al	PERSON
dpc-3895	108	2	nma	ORG
dpc-3895	110	1	74.74%	PERCENT
dpc-3895	110	2	74/99	CARDINAL
dpc-3895	110	3	27.27%	PERCENT
dpc-3895	110	4	27/99	CARDINAL
dpc-3895	110	5	17%	PERCENT
dpc-3895	110	6	17/99	CARDINAL
dpc-3895	111	1	secukinumab initiation	PERSON
dpc-3895	111	2	week 4	DATE
dpc-3895	111	3	fold	CARDINAL
dpc-3895	111	4	37/44	CARDINAL
dpc-3895	111	5	84.1%	PERCENT
dpc-3895	112	1	week 5	DATE
dpc-3895	112	2	5.29	CARDINAL
dpc-3895	113	1	1.49	CARDINAL
dpc-3895	113	2	5	CARDINAL
dpc-3895	113	3	spga	ORG
dpc-3895	113	4	0/1	CARDINAL
dpc-3895	113	5	week 4	DATE
dpc-3895	113	6	11	CARDINAL
dpc-3895	114	1	7	CARDINAL
dpc-3895	114	2	more than 2 years	DATE
dpc-3895	115	1	3	CARDINAL
dpc-3895	115	2	week 16	DATE
dpc-3895	115	3	3	CARDINAL
dpc-3895	116	1	ae	ORG
dpc-3895	117	1	3	CARDINAL
dpc-3895	117	2	ae	ORG
dpc-3895	117	3	two	CARDINAL
dpc-3895	117	4	1	CARDINAL
dpc-3895	117	5	1	CARDINAL
dpc-3895	118	1	four	CARDINAL
dpc-3895	118	2	week	DATE
dpc-3895	118	3	2	CARDINAL
dpc-3895	119	1	75 4 99	PERCENT
dpc-3895	119	2	55.6%	PERCENT
dpc-3895	119	3	16 96 84/96	PERCENT
dpc-3895	119	4	87.5%	PERCENT
dpc-3895	119	5	52 81 70/81	PERCENT
dpc-3895	119	6	86.4%	PERCENT
dpc-3895	119	7	55 52/55	CARDINAL
dpc-3895	119	8	94.5%	PERCENT
dpc-3895	119	9	156	CARDINAL
dpc-3895	119	10	30 29/30	CARDINAL
dpc-3895	119	11	96.7%	PERCENT
dpc-3895	119	12	208	CARDINAL
dpc-3895	119	13	9 9/9	CARDINAL
dpc-3895	119	14	100%	PERCENT
dpc-3895	119	15	90	CARDINAL
dpc-3895	119	16	99 25/99	CARDINAL
dpc-3895	119	17	25.3%	PERCENT
dpc-3895	119	18	16 96 67/96	PERCENT
dpc-3895	119	19	69.8%	PERCENT
dpc-3895	120	1	52 81 70/81	PERCENT
dpc-3895	120	2	77.8%	PERCENT
dpc-3895	120	3	104 55 43/55	CARDINAL
dpc-3895	120	4	78.2%	PERCENT
dpc-3895	120	5	156	CARDINAL
dpc-3895	120	6	30 24/30	CARDINAL
dpc-3895	120	7	80.0%	PERCENT
dpc-3895	120	8	208	CARDINAL
dpc-3895	120	9	9 9/9	CARDINAL
dpc-3895	120	10	100%	PERCENT
dpc-3895	120	11	100	CARDINAL
dpc-3895	120	12	14.1%	PERCENT
dpc-3895	120	13	16 96	DATE
dpc-3895	120	14	49.0%	PERCENT
dpc-3895	120	15	52 81 35/81	PERCENT
dpc-3895	120	16	43.2%	PERCENT
dpc-3895	120	17	55 26/55	CARDINAL
dpc-3895	120	18	47.3%	PERCENT
dpc-3895	120	19	156	CARDINAL
dpc-3895	120	20	30 15/30	CARDINAL
dpc-3895	120	21	50.0%	PERCENT
dpc-3895	120	22	208	CARDINAL
dpc-3895	120	23	9 8/9	CARDINAL
dpc-3895	120	24	88.9%	PERCENT
dpc-3895	121	1	6	CARDINAL
dpc-3895	122	1	2024;14(2):e2024119	CARDINAL
dpc-3895	123	1	5-year	DATE
dpc-3895	123	2	8	CARDINAL
dpc-3895	124	1	secukinumab	PERSON
dpc-3895	124	2	11	CARDINAL
dpc-3895	126	1	74,74%	PERCENT
dpc-3895	126	2	74/99	CARDINAL
dpc-3895	126	3	27.27%	PERCENT
dpc-3895	126	4	27/99	CARDINAL
dpc-3895	126	5	17%	PERCENT
dpc-3895	126	6	17/99	CARDINAL
dpc-3895	127	1	secukinumab	PERSON
dpc-3895	127	2	fold	CARDINAL
dpc-3895	127	3	37/44	CARDINAL
dpc-3895	127	4	84.1%	PERCENT
dpc-3895	128	1	week 5	DATE
dpc-3895	128	2	5.29	CARDINAL
dpc-3895	129	1	1.49	CARDINAL
dpc-3895	129	2	5	CARDINAL
dpc-3895	129	3	spga	ORG
dpc-3895	129	4	0/1	CARDINAL
dpc-3895	129	5	week 4	DATE
dpc-3895	131	1	first	ORDINAL
dpc-3895	131	2	fold	CARDINAL
dpc-3895	132	1	il23	PRODUCT
dpc-3895	133	1	19840	CARDINAL
dpc-3895	133	2	28	CARDINAL
dpc-3895	133	3	first	ORDINAL
dpc-3895	133	4	0/1	PRODUCT
dpc-3895	133	5	iga	ORG
dpc-3895	133	6	0/1	PRODUCT
dpc-3895	133	7	0/1	PRODUCT
dpc-3895	133	8	second	ORDINAL
dpc-3895	133	9	week 12 or	DATE
dpc-3895	134	1	7	CARDINAL
dpc-3895	135	1	secukinumab	PERSON
dpc-3895	138	1	augustin et al	PERSON
dpc-3895	138	2	1 january 2015 to 31	DATE
dpc-3895	139	1	43	CARDINAL
dpc-3895	139	2	12 weeks	DATE
dpc-3895	139	3	72%/50%/36%	PERCENT
dpc-3895	141	1	secukinumab	PERSON
dpc-3895	141	2	almost 100%	PERCENT
dpc-3895	141	3	75	CARDINAL
dpc-3895	141	4	78.2%	PERCENT
dpc-3895	141	5	90	CARDINAL
dpc-3895	141	6	47.3%	PERCENT
dpc-3895	141	7	100	CARDINAL
dpc-3895	141	8	week 104	DATE
dpc-3895	141	9	3	CARDINAL
dpc-3895	142	1	week	DATE
dpc-3895	142	2	76y	CARDINAL
dpc-3895	142	3	week 52	DATE
dpc-3895	142	4	80	CARDINAL
dpc-3895	142	5	49y	CARDINAL
dpc-3895	142	6	week 24	DATE
dpc-3895	142	7	week 52	DATE
dpc-3895	142	8	55y	CARDINAL
dpc-3895	142	9	week 48	DATE
dpc-3895	142	10	week 112	CARDINAL
dpc-3895	142	11	week 108	DATE
dpc-3895	142	12	160	CARDINAL
dpc-3895	142	13	31y	CARDINAL
dpc-3895	142	14	week 52	DATE
dpc-3895	142	15	week 108	DATE
dpc-3895	142	16	59y	DATE
dpc-3895	142	17	53y	DATE
dpc-3895	142	18	acitretin topical	PERSON
dpc-3895	142	19	week 52	DATE
dpc-3895	142	20	120	CARDINAL
dpc-3895	142	21	55y	CARDINAL
dpc-3895	142	22	week 16	DATE
dpc-3895	142	23	47	CARDINAL
dpc-3895	142	24	week 16	DATE
dpc-3895	142	25	52y	CARDINAL
dpc-3895	142	26	adalimumab	PERSON
dpc-3895	143	1	week	DATE
dpc-3895	144	1	20	CARDINAL
dpc-3895	144	2	42y	CARDINAL
dpc-3895	144	3	152	CARDINAL
dpc-3895	145	1	2024;14(2):e2024119 7	DATE
dpc-3895	145	2	secukinumab	PERSON
dpc-3895	146	1	5 weeks	DATE
dpc-3895	147	1	the 208 weeks	DATE
dpc-3895	148	1	4-year	DATE
dpc-3895	148	2	greece	GPE
dpc-3895	149	1	novartis	ORG
dpc-3895	149	2	greece	GPE
dpc-3895	150	1	1	CARDINAL
dpc-3895	150	2	schupp cw	ORG
dpc-3895	150	3	armstrong aw	PERSON
dpc-3895	150	4	the united states	GPE
dpc-3895	151	1	j am	PERSON
dpc-3895	152	1	2014;70(3):512-516	CARDINAL
dpc-3895	153	1	10.1016	CARDINAL
dpc-3895	153	2	j.jaad.2013.11.013	GPE
dpc-3895	154	1	24388724	DATE
dpc-3895	155	1	2	CARDINAL
dpc-3895	155	2	dopytalska k	PERSON
dpc-3895	155	3	szymańska e	GPE
dpc-3895	155	4	walecka i. psoriasis	PERSON
dpc-3895	157	1	2018;56(6):392-398	CARDINAL
dpc-3895	158	1	10.5114	CARDINAL
dpc-3895	159	1	30647487	DATE
dpc-3895	161	1	hong jj	GPE
dpc-3895	161	2	liao wj	PERSON
dpc-3895	164	1	2021;11(3):833-844	CARDINAL
dpc-3895	165	1	10.1007	CARDINAL
dpc-3895	166	1	33914293	CARDINAL
dpc-3895	168	1	4	CARDINAL
dpc-3895	168	2	prinz jc	PERSON
dpc-3895	168	3	gottlieb ab	PERSON
dpc-3895	168	4	secukinumab	PERSON
dpc-3895	170	1	2015;172(2):484-493	CARDINAL
dpc-3895	171	1	10.1111	CARDINAL
dpc-3895	172	1	25132411	DATE
dpc-3895	173	1	lee jh	PERSON
dpc-3895	173	2	tsai tf	PERSON
dpc-3895	173	3	secukinumab	PERSON
dpc-3895	173	4	asian	NORP
dpc-3895	174	1	the american academy	ORG
dpc-3895	175	1	2015;72(5	CARDINAL
dpc-3895	175	2	1	DATE
dpc-3895	175	3	ab249	GPE
dpc-3895	176	1	10.1016	CARDINAL
dpc-3895	177	1	6	CARDINAL
dpc-3895	177	2	rrompoti n	PERSON
dpc-3895	177	3	katsimbri p	ORG
dpc-3895	177	4	kokkalis g	PERSON
dpc-3895	178	1	104-week	DATE
dpc-3895	180	1	2019;32(5):e13006	CARDINAL
dpc-3895	180	2	10.1111	CARDINAL
dpc-3895	181	1	31228319	DATE
dpc-3895	182	1	7	CARDINAL
dpc-3895	182	2	bai f	PERSON
dpc-3895	182	3	li gg	PERSON
dpc-3895	182	4	liu q	PERSON
dpc-3895	182	5	niu	ORG
dpc-3895	182	6	li	PERSON
dpc-3895	182	7	ma h.	PERSON
dpc-3895	182	8	secukinumab	GPE
dpc-3895	182	9	ixekizumab	PERSON
dpc-3895	182	10	guselkumab	PERSON
dpc-3895	182	11	tildrakizumab	PERSON
dpc-3895	182	12	secondary	ORDINAL
dpc-3895	183	1	anti-il17	NORP
dpc-3895	183	2	anti-il12/23	NORP
dpc-3895	183	3	16	CARDINAL
dpc-3895	184	1	only 11	CARDINAL
dpc-3895	185	1	seven	CARDINAL
dpc-3895	185	2	more than 2 years	DATE
dpc-3895	186	1	three	CARDINAL
dpc-3895	186	2	week 16	DATE
dpc-3895	186	3	3	CARDINAL
dpc-3895	187	1	6,10,17].additionally	CARDINAL
dpc-3895	187	2	almost half	CARDINAL
dpc-3895	187	3	secukinumab	PERSON
dpc-3895	187	4	5/11	CARDINAL
dpc-3895	187	5	45%	PERCENT
dpc-3895	187	6	at least one	CARDINAL
dpc-3895	188	1	18	CARDINAL
dpc-3895	189	1	january 2022	DATE
dpc-3895	189	2	300 mg	QUANTITY
dpc-3895	189	3	2 weeks	DATE
dpc-3895	189	4	90 kg	QUANTITY
dpc-3895	190	1	19	CARDINAL
dpc-3895	191	1	secukinumab	PERSON
dpc-3895	191	2	the 208 weeks	DATE
dpc-3895	192	1	only three	CARDINAL
dpc-3895	192	2	aes	ORG
dpc-3895	192	3	secukinumab	PERSON
dpc-3895	194	1	one	CARDINAL
dpc-3895	194	2	42-year-old	DATE
dpc-3895	194	3	week 152	DATE
dpc-3895	197	1	20	CARDINAL
dpc-3895	198	1	three	CARDINAL
dpc-3895	200	1	aes	ORG
dpc-3895	201	1	8	CARDINAL
dpc-3895	202	1	2024;14(2):e2024119	CARDINAL
dpc-3895	203	1	2019;12:249-253	CARDINAL
dpc-3895	204	1	10.2147/	CARDINAL
dpc-3895	205	1	31118728	DATE
dpc-3895	207	1	14	DATE
dpc-3895	208	1	reich k	PERSON
dpc-3895	208	2	sullivan j	PERSON
dpc-3895	208	3	arenberger	PERSON
dpc-3895	208	4	secukinumab	PERSON
dpc-3895	208	5	2.5-year	DATE
dpc-3895	210	1	2021;184(3):425-436	CARDINAL
dpc-3895	211	1	10.1111	CARDINAL
dpc-3895	212	1	32479641	CARDINAL
dpc-3895	213	1	15	CARDINAL
dpc-3895	214	1	gottlieb ab	PERSON
dpc-3895	214	2	kubanov	GPE
dpc-3895	214	3	2·5-year	DATE
dpc-3895	216	1	889-899	QUANTITY
dpc-3895	216	2	10.1111	CARDINAL
dpc-3895	217	1	31286480	DATE
dpc-3895	218	1	16	CARDINAL
dpc-3895	219	1	parodi a. biological	PERSON
dpc-3895	221	1	2020;33(1):e13110	CARDINAL
dpc-3895	222	1	10.1111	CARDINAL
dpc-3895	222	2	dth.13110	GPE
dpc-3895	223	1	31595647	DATE
dpc-3895	224	1	17	CARDINAL
dpc-3895	225	1	morais p	PERSON
dpc-3895	225	2	ferreira p	PERSON
dpc-3895	225	3	secukinumab	GPE
dpc-3895	225	4	portugal	GPE
dpc-3895	227	1	2022;35(7):e15510	CARDINAL
dpc-3895	227	2	10.1111/dth.15510	MONEY
dpc-3895	228	1	35419886	DATE
dpc-3895	229	1	18	CARDINAL
dpc-3895	229	2	yiu zzn	PERSON
dpc-3895	229	3	mason kj	PERSON
dpc-3895	229	4	hampton pj	PERSON
dpc-3895	229	5	adalimumab	PERSON
dpc-3895	229	6	the british association of dermatologists biologics	ORG
dpc-3895	231	1	2020;183(2):294	CARDINAL
dpc-3895	232	1	10.1111	CARDINAL
dpc-3895	233	1	pmid	PERSON
dpc-3895	233	2	32124442	DATE
dpc-3895	234	1	19	CARDINAL
dpc-3895	234	2	secukinumab	PERSON
dpc-3895	234	3	10	CARDINAL
dpc-3895	236	1	mehta p	PERSON
dpc-3895	236	2	lawrence a	PERSON
dpc-3895	236	3	aggarwal a. paradoxical	PERSON
dpc-3895	236	4	interleukin-17	DATE
dpc-3895	237	1	ann rheum dis	PERSON
dpc-3895	238	1	2023;82(6):e152	CARDINAL
dpc-3895	239	1	10.1136/annrheumdis-2020-218719	CARDINAL
dpc-3895	240	1	32988844	DATE
dpc-3895	242	1	j immunol	PERSON
dpc-3895	243	1	2019;2019:2546161	CARDINAL
dpc-3895	244	1	10.1155/2019/2546161	TIME
dpc-3895	245	1	31583255	CARDINAL
dpc-3895	247	1	8	CARDINAL
dpc-3895	247	2	bissonnette r	PERSON
dpc-3895	247	3	luger t	PERSON
dpc-3895	247	4	secukinumab	PERSON
dpc-3895	247	5	5 years	DATE
dpc-3895	249	1	2018;32(9):1507	CARDINAL
dpc-3895	249	2	1514	CARDINAL
dpc-3895	250	1	10.1111	CARDINAL
dpc-3895	251	1	pmid	PERSON
dpc-3895	251	2	29444376	DATE
dpc-3895	252	1	pmc6175198	ORG
dpc-3895	253	1	langley rg	PERSON
dpc-3895	253	2	secukinumab long-term	PERSON
dpc-3895	255	1	2023;188(2):198-207	CARDINAL
dpc-3895	256	1	10.1093	CARDINAL
dpc-3895	257	1	36763857	DATE
dpc-3895	258	1	10	CARDINAL
dpc-3895	258	2	augustin m	PERSON
dpc-3895	258	3	von kiedrowski	PERSON
dpc-3895	258	4	secukinumab	PERSON
dpc-3895	260	1	1796-1804	DATE
dpc-3895	261	1	10.1111/jdv.18329	MONEY
dpc-3895	262	1	35696305	DATE
dpc-3895	263	1	11	CARDINAL
dpc-3895	263	2	bagel j	PERSON
dpc-3895	263	3	duffin kc	PERSON
dpc-3895	263	4	moore	PERSON
dpc-3895	264	1	24-week	DATE
dpc-3895	264	2	3b	CARDINAL
dpc-3895	265	1	j am	PERSON
dpc-3895	266	1	2017;77(4):667-674	CARDINAL
dpc-3895	267	1	10.1016	CARDINAL
dpc-3895	268	1	pmid	PERSON
dpc-3895	268	2	28780364	CARDINAL
dpc-3895	269	1	12	CARDINAL
dpc-3895	270	1	kircik l	ORG
dpc-3895	270	2	weiss	ORG
dpc-3895	270	3	meng x	PERSON
dpc-3895	270	4	52 weeks	DATE
dpc-3895	270	5	four	CARDINAL
dpc-3895	270	6	3	CARDINAL
dpc-3895	271	1	heidelb	PERSON
dpc-3895	272	1	2016;6(4):627-638	CARDINAL
dpc-3895	273	1	10.1007/	CARDINAL
dpc-3895	273	2	s13555-016-0139-0	LAW
dpc-3895	274	1	27573260	DATE
dpc-3895	276	1	13	CARDINAL
dpc-3895	276	2	kivelevitch d	ORG
dpc-3895	276	3	amin s	PERSON
dpc-3895	277	1	clin	PERSON